{"nctId":"NCT00105196","briefTitle":"A Study of Aripiprazole in Patients With Major Depressive Disorder","startDateStruct":{"date":"2005-03"},"conditions":["Major Depressive Disorder"],"count":349,"armGroups":[{"label":"A1","type":"EXPERIMENTAL","interventionNames":["Drug: Aripiprazole+ ADT"]},{"label":"A2","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo+ ADT"]}],"interventions":[{"name":"Aripiprazole+ ADT","otherNames":["Abilify"]},{"name":"Placebo+ ADT","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men and women, 18-65 years old who have experienced single or recurrent, non-psychotic episodes of Major Depressive Disorder, with the current episode of minimally 8 weeks in duration.\n* Treatment history of an inadequate response to at least one and no more than three adequate antidepressant trials.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change in the Montgomery Åsberg Depression Rating Scale (MADRS)","description":"Mean change from Week 8 (baseline) to Week 14 in MADRS total score, a 10-item, ordinal rating scale (0=no symptoms; 60=most severe symptoms). Change from baseline=postbaseline score - baseline score. A negative change score indicates improvement.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.12","spread":"0.74"},{"groupId":"OG001","value":"-6.39","spread":"0.74"}]}]}]},{"type":"SECONDARY","title":"Mean Change in Sheehan Disability Scale (SDS) Mean Score","description":"Mean change from Week 8 (baseline) to Week 14 in SDS Mean Score, a 3-item, ordinal scale (0=unimpaired; 30=highly impaired). Change from baseline=postbaseline score - baseline score. A negative change score indicates improvement.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.22","spread":"0.21"},{"groupId":"OG001","value":"-0.80","spread":"0.20"}]}]}]},{"type":"SECONDARY","title":"Mean Change in SDS Item Score (Social Life)","description":"Mean change from Week 8 (baseline) to Week 14 in SDS Social Life Item Score, 1 item from a 3-item, ordinal scale (0=unimpaired; 10=highly impaired). Change from baseline=postbaseline score - baseline score. A negative change score indicates improvement.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.18","spread":"0.24"},{"groupId":"OG001","value":"-0.65","spread":"0.23"}]}]}]},{"type":"SECONDARY","title":"Mean Change in SDS Item Score (Family Life)","description":"Mean change from Week 8 (Baseline) to Week 14 in SDS Family Life Item Score, 1 item from a 3-item, ordinal scale (0=unimpaired; 10=highly impaired). Change from baseline=postbaseline score - baseline score. A negative change score indicates improvement.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.39","spread":"0.24"},{"groupId":"OG001","value":"-0.82","spread":"0.23"}]}]}]},{"type":"SECONDARY","title":"Mean Change in SDS Item Score (Work/School)","description":"Mean change from Week 8 (baseline) to Week 14 in SDS Work/School Item Score, 1 item from a 3-item, ordinal scale (0=unimpaired; 10=highly impaired). Change from baseline=postbaseline score - baseline score. A negative change score indicates improvement.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.75","spread":"0.28"},{"groupId":"OG001","value":"-0.67","spread":"0.26"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"MADRS Response","description":"Number of subjects with a ≥50 percent reduction from Week 8 (baseline) in MADRS Total Score, a 10-item, ordinal rating scale to assess the severity of depressive symptoms (0=no symptoms; 60=most severe symptoms).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"124","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Clinical Global Impression (CGI)-Improvement Response","description":"Number of subjects with response relative to Week 8 (baseline). Response defined as score of 1 (very much improved) or 2 (much improved) on a 7-point, ordinal scale (1=very much improved; 7=very much worse).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"109","spread":null},{"groupId":"OG001","value":"74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":null},{"groupId":"OG001","value":"95","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"MADRS Remission","description":"Number of subjects in remission. Remission defined as as MADRS Total Score of \\<10 at 14 weeks, and a reduction of ≥50 percent from Week 8 (baseline) in MADRS, a 10-item, ordinal rating scale (0=no symptoms; 60=most severe symptoms).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"110","spread":null},{"groupId":"OG001","value":"137","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":176},"commonTop":["AKATHISIA","HEADACHE","RESTLESSNESS","UPPER RESPIRATORY TRACT INFECTION","INSOMNIA"]}}}